PRIVIA HEALTH GR. DL-,01 Aktie

Privia Health Group will report results for the most recent quarter on 06.08.2026. Fourteen analysts expect average EPS of $0.068 (prior year $0.020) and 19 analysts forecast revenue of $597.7 million (prior year $521.2 million). For the current fiscal year, consensus estimates are $0.244 earnings per share and $2.42 billion in revenue, versus $0.180 and $2.12 billion in the prior year. » More on finanzen.net

Shareholders of Privia Health Group approved all three proposals at the 2026 annual general meeting, including the election of directors Nancy Cocozza, David King and Francis Soistman, approval of performance-based compensation and the reappointment of PricewaterhouseCoopers as auditor for 2026. Privia has a market capitalization of USD 2.85 billion, more cash than debt and a high P/E ratio of 134.87. In Q1 2026 the company beat revenue expectations with USD 603.85 million but missed EPS forecasts (EPS USD 0.02 vs. expected USD 0.0746). An analysis calls the stock undervalued at the current price and sees upside potential. » More on de.investing.com

Privia Health reported Q1 2026 revenue of $603.85 million, topping the consensus of $559.49 million, while EPS was only $0.02, significantly missing the forecast of $0.0746. Adjusted EBITDA rose 36.3% to $36.7 million; practice revenues increased 14.6%. The company shows a debt-free balance sheet and a strong cash position and reaffirmed full-year guidance of roughly $150 million in adjusted EBITDA. Despite strong revenue growth, the stock fell sharply after the release as investors focused on weak profitability. » More on de.investing.com

Privia Health reported revenue of $603.85 million in Q1 2026 and strong operational growth, including 13.6% more connected providers (5,535) and 26.5% more insured lives under management (1.6 million). Adjusted EBITDA rose 36.3% to $36.7 million, but earnings per share of $0.02 missed analyst estimates by a wide margin and highlighted a gross margin of 9.87% as a weak spot. The stock fell on the news, while management largely reaffirmed the full-year guidance and raised the insured-lives expectation to 1.6–1.625 million. Privia emphasized a robust cash position and plans to drive margin improvement through cost management and operational excellence. » More on de.investing.com

J.P. Morgan raised its price target on Privia Health from $33 to $35 and maintained an Overweight rating, implying about 57% upside, while Truist lifted its target from $31 to $33 and reiterated a Buy rating with roughly 48% upside. The broker upgrades follow a strong fourth-quarter report, though management noted a sequential decline in fee-for-service collections driven by a higher share of specialist visits and retroactive billing issues in California and North Texas. Privia Health provides tech-enabled physician support and value-based care services to health systems and physicians. » More on finance.yahoo.com